Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARS Pharmaceuticals, Inc.SBTX · Entity 883 | Director | June 10, 2022 | June 13, 2022 |
| CARLSMED, INC.CARL · Entity 5551 | Director | June 03, 2026 | June 22, 2026 |
| Edgewise Therapeutics, Inc.EWTX · Entity 3965 | Director | June 05, 2026 | July 17, 2026 |
| Omada Health, Inc.OMDA · Entity 2364 | Director | October 05, 2026 | October 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARS Pharmaceuticals, Inc.
Report date June 10, 2022 · Filed June 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.18 · Expires 2032-06-09 | Direct | 18,000 |
Reported balance
After 2022-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-10 · Grant · Acquired 18,000 · Balance 18,000 F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
CARLSMED, INC.
Report date June 03, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 497,697 |
Reported balance
After 2026-06-03 transaction · row 1
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 13,698 · Balance 497,697 F1: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 4,305,806 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 4,305,806 F2: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII"). F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 218,524 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 218,524 F3: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A"). F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 1,117,743 |
Reported balance
Holding disclosure · report date 2026-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,117,743 F4: Stock held by U.S. Venture Partners Select Fund I, L.P., ("USVP SFI") on its own behalf and as nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A"). F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Constitutes an award of restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. The RSUs will vest in full on the earlier of (i) the day before the Issuer's 2027 annual meeting of stockholders or (ii) June 3, 2027, subject, in all cases, to the Reporting Person's continued service as a member of the Board of Directors through such vesting date.
F2: Stock held by U.S. Venture Partners XII, L.P. ("USVP XII").
F3: Stock held by U.S. Venture Partners XII-A, L.P. ("USVP XII-A").
F4: Stock held by U.S. Venture Partners Select Fund I, L.P., ("USVP SFI") on its own behalf and as nominee for U.S. Venture Partners Select Fund I-A, L.P. ("USVP SFI-A").
F5: Presidio Management Group XII, L.L.C ("PMG XII") is the general partner of USVP XII and USVP XII-A. Presidio Management Group Select Fund I, L.L.C ("PMG SFI," and, together with USVP XII, USVP XII-A, USVP SFI, USVP SFI-A, and PMG XII, "USVP") is the general partner of USVP SFI and USVP SFI-A. The Reporting Person is a managing member of PMG XII and PMG SFI and may be deemed to share voting and dispositive power over the stock held by USVP. The Reporting Person disclaims beneficial ownership of such stock, except to the extent of any pecuniary interest therein.
Edgewise Therapeutics, Inc.
Report date June 05, 2026 · Filed July 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.59 · Expires 2036-06-05 | Direct | 16,377 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 16,377 · Balance 16,377 F1: 100% of the Stock Options Granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the Stock Options Granted on June 5, 2026 will become vested on the earlier of (i) June 5, 2027 or (ii) the business day prior to the 2027 annual meeting of shareholders.
Omada Health, Inc.
Report date October 05, 2026 · Filed October 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 192,571 |
Reported balance
After 2026-10-05 transaction · row 1
1 source rowRow 1 · 2026-10-05 · Grant · Acquired 694 · Balance 192,571 F1: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units ("RSUs") that were granted pursuant to the Issuer's Non-Employee Director Compensation Program (the "Program") in lieu of retainer fees. Each RSU represents the right to receive one (1) share of Common Stock, with settlement to take place either (i) on a date selected by the Reporting Person pursuant to the Program or (ii) as otherwise provided by the Program.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BOX INC
Report date June 02, 2017 · Filed June 08, 2017 · Amendment
Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, FEDERMAN IRWIN, LIDDLE DAVID E, Matteucci Paul A, Tansey Casey M, YOUNG PHILIP M
Section 16 reporting ended · disclosed 2017-06-08. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP IX | 0 |
Last balance in matching sequence
After 2017-06-02 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2017-06-02 · Conversion · Acquired 8,000,000 · Balance 8,000,000 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 2 · 2017-06-02 · Other · Disposed 8,000,000 · Balance 0 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F2: Prorata distribution in kind from the partnership without consideration to its limited partners. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Class B Common StockSEC Table II · derivative / convertible security | IndirectDirectly owned by USVP IX | 3,713,775 |
Reported balance
After 2017-06-02 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2017-06-02 · Conversion · Disposed 8,000,000 · Balance 3,713,775 F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date. F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Class B Common Stock is convertible into one share of Class A Common Stock at the option of the holder and has no expiration date.
F2: Prorata distribution in kind from the partnership without consideration to its limited partners.
F3: The shares are held of record by U.S. Venture Partners IX, L.P. ("USVP IX"). Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Steven M. Krausz, a director of the Issuer, and each of Irwin Federman, David E. Liddle, Paul A Matteucci, Jonathan D. Root, Casey M. Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
INTERMOLECULAR INC
Report date November 08, 2018 · Filed November 13, 2018
Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, KRAUSZ STEVEN M, LIDDLE DAVID E, Matteucci Paul A, Tansey Casey M, YOUNG PHILIP M
Section 16 reporting ended · disclosed 2018-11-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by USVP IX | 0 |
Reported balance
After 2018-11-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-11-08 · Other · Disposed 4,280,779 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | Direct | 856,155 |
Reported balance
After 2018-11-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-11-08 · Other · Acquired 856,155 · Balance 856,155 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-08 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-11-08 · Other · Disposed 856,155 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Steven Krausz | 97,593 |
Last balance in matching sequence
After 2018-11-13 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 4 · 2018-11-08 · Other · Acquired 102,093 · Balance 102,093 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 5 · 2018-11-12 · Sale · Disposed 2,100 · Balance 99,993 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Row 6 · 2018-11-13 · Sale · Disposed 2,400 · Balance 97,593 F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by David Liddle | 69,609 |
Reported balance
After 2018-11-08 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2018-11-08 · Other · Acquired 69,609 · Balance 69,609 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Paul Matteucci | 60,408 |
Reported balance
After 2018-11-08 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2018-11-08 · Other · Acquired 60,408 · Balance 60,408 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Jonathan Root | 85,851 |
Reported balance
After 2018-11-08 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2018-11-08 · Other · Acquired 85,851 · Balance 85,851 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Casey Tansey | 60,336 |
Reported balance
After 2018-11-08 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2018-11-08 · Other · Acquired 60,336 · Balance 60,336 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common Stock, $0.001 per shareSEC Table I · non-derivative | IndirectDirectly owned by Philip Young | 82,370 |
Reported balance
After 2018-11-08 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2018-11-08 · Other · Acquired 82,370 · Balance 82,370 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Inari Medical, Inc.
Report date February 19, 2025 · Filed February 20, 2025
Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-02-19 transaction · row 1
1 source rowRow 1 · 2025-02-19 · Other · Disposed 541,149 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectDirectly Owned by Spouse | 0 |
Reported balance
After 2025-02-19 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-02-19 · Other · Disposed 335 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.
F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Inspire Medical Systems, Inc.
Report date November 08, 2018 · Filed November 14, 2018
Jointly reported with Presidio Management Group IX, L.L.C., U S Venture Partners IX L P, FEDERMAN IRWIN, KRAUSZ STEVEN M, LIDDLE DAVID E, Matteucci Paul A, YOUNG PHILIP M
Section 16 reporting ended · disclosed 2018-11-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP IX | 1,084,127 |
Reported balance
After 2018-11-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-11-08 · Other · Disposed 1,084,127 · Balance 1,084,127 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | Direct | 216,825 |
Reported balance
After 2018-11-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-11-08 · Other · Acquired 216,825 · Balance 216,825 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2018-11-08 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-11-08 · Other · Disposed 216,825 · Balance 0 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Irwin Federman | 18,212 |
Reported balance
After 2018-11-08 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-11-08 · Other · Acquired 18,212 · Balance 18,212 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Steven Krausz | 22,573 |
Reported balance
After 2018-11-08 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2018-11-08 · Other · Acquired 22,573 · Balance 22,573 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by David Liddle | 15,391 |
Reported balance
After 2018-11-08 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2018-11-08 · Other · Acquired 15,391 · Balance 15,391 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Paul Matteucci | 13,356 |
Reported balance
After 2018-11-08 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2018-11-08 · Other · Acquired 13,356 · Balance 13,356 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Jonathan Root | 18,982 |
Reported balance
After 2018-11-08 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2018-11-08 · Other · Acquired 18,982 · Balance 18,982 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by Philip Young | 18,212 |
Reported balance
After 2018-11-08 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2018-11-08 · Other · Acquired 18,212 · Balance 18,212 F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners.
F2: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein.
OncoMed Pharmaceuticals Inc
Report date April 23, 2019 · Filed April 23, 2019
Section 16 reporting ended · disclosed 2019-04-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-04-23 transaction · row 1
1 source rowRow 1 · 2019-04-23 · Other · Disposed 121,020 · Balance 0 F1: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own. F2: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own.
F2: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock.
eFFECTOR Therapeutics, Inc.
Report date August 01, 2022 · Filed August 03, 2022
Jointly reported with Presidio Management Group X LLC, US VENTURE PARTNERS X LP, USVP X AFFILIATES LP, Tansey Casey M
Section 16 reporting ended · disclosed 2022-08-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by USVP X | 3,981,940 |
Last balance in matching sequence
After 2022-08-03 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2022-08-01 · Sale · Disposed 25,896 · Balance 4,066,868 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 3 · 2022-08-02 · Sale · Disposed 27,348 · Balance 4,039,520 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 5 · 2022-08-03 · Sale · Disposed 57,580 · Balance 3,981,940 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectDirectly owned by AFF X | 127,569 |
Last balance in matching sequence
After 2022-08-03 transaction · row 6
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 2 · 2022-08-01 · Sale · Disposed 807 · Balance 130,218 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 4 · 2022-08-02 · Sale · Disposed 853 · Balance 129,365 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Row 6 · 2022-08-03 · Sale · Disposed 1,796 · Balance 127,569 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.77 to $0.81, inclusive for sales on 8/1/22; prices ranging from $0.78 to $0.83, inclusive for sales on 8/2/22; and prices ranging from $0.79 to $0.83, inclusive for sales on 8/3/22;. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
F2: Presidio Management Group X, L.L.C. ("PMG X"), the general partner of each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates L.P. ("AFF X") (together, the "USVP X Funds"), has sole voting and dispositive power with respect to the shares held by the USVP X Funds. Jonathan Root is a managing member of PMG X with additional rights with respect to the Issuer's securities, and may be deemed to have sole voting and dispositive power with respect to the shares. Casey Tansey is the sole managing partner of PMG X and may be deemed to have sole dispositive power over the reported securities held by the USVP X Funds and may be deemed to have shared voting power over the reported securities held by the USVP X Funds. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 13, 2021 Filed May 17, 2021 22:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 93,972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-004765 · form4.xml · nonDerivative · entry 5 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,864 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5 · ownership.direct: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. Shares are held directly by the Reporting Person. Read SEC document |
| May 13, 2021 Filed May 17, 2021 22:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 685,826 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-004765 · form4.xml · nonDerivative · entry 4 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by PMG X Disclosed balance after: 0 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F4 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration to its members (the "PMG Distribution"). The Reporting Person, a director of the Issuer, is a managing member of PMG X with additional rights with respect to the shares, and may be deemed to have sole voting and dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities held by PMG X, except to the extent of any pecuniary interest therein. Read SEC document |
| May 13, 2021 Filed May 17, 2021 22:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 685,826 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-004765 · form4.xml · nonDerivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by PMG X Disclosed balance after: 685,826 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F3 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP X Funds, without additional consideration. The Reporting Person, a director of the Issuer, is a managing member of PMG X with additional rights with respect to the shares, and deemed to have sole voting and dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| May 13, 2021 Filed May 17, 2021 22:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 83,813 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-004765 · form4.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 0 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), without additional consideration, to its partners. Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. The Reporting Person, a director of the Issuer, is a managing member of PMG X with additional rights with respect to such shares, and deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| May 13, 2021 Filed May 17, 2021 22:44 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 2,619,872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001062993-21-004765 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 0 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), without additional consideration, to its partners. Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. The Reporting Person, a director of the Issuer, is a managing member of PMG X with additional rights with respect to such shares, and deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 23:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | ConversionSeries C Preferred Stock · Derivative | 455,229 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023869 · doc4.xml · derivative · entry 5 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 455,229 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held of record by U.S. Venture Partners XI, L.P. ("USVP XI"). Presidio Management Group XI, L.L.C. ("PMG XI"), the general partner of USVP XI, has sole voting and dispositive power with respect to the shares held by USVP XI. The Reporting Person is a managing member of PMG XI with additional rights with respect to the issuer's securities, and may be deemed to have sole voting and dispositive power with respect to such shares. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 23:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | ConversionSeries B-2 Preferred Stock · Derivative | 1,366,707 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023869 · doc4.xml · derivative · entry 4 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,366,707 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held of record by U.S. Venture Partners XI, L.P. ("USVP XI"). Presidio Management Group XI, L.L.C. ("PMG XI"), the general partner of USVP XI, has sole voting and dispositive power with respect to the shares held by USVP XI. The Reporting Person is a managing member of PMG XI with additional rights with respect to the issuer's securities, and may be deemed to have sole voting and dispositive power with respect to such shares. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 23:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | ConversionSeries B-1 Preferred Stock · Derivative | 1,651,607 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023869 · doc4.xml · derivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 1,651,607 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held of record by U.S. Venture Partners XI, L.P. ("USVP XI"). Presidio Management Group XI, L.L.C. ("PMG XI"), the general partner of USVP XI, has sole voting and dispositive power with respect to the shares held by USVP XI. The Reporting Person is a managing member of PMG XI with additional rights with respect to the issuer's securities, and may be deemed to have sole voting and dispositive power with respect to such shares. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 23:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | PurchaseCommon Stock | 15,625 | $16.00 | $250,000.00 |
DisclosureSEC source: 0001209191-21-023869 · doc4.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,625 Read SEC document |
| March 30, 2021 Filed Mar 31, 2021 23:12 UTC | Edgewise Therapeutics, Inc. EWTX · Entity 3965 | ConversionCommon Stock | 3,473,543 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023869 · doc4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,473,543 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Each share of Series A Preferred Stock, Series B-1 Preferred Stock, Series B-2 Preferred Stock and Series C Preferred Stock converted into one share of the Issuer's Common Stock immediately prior to the completion of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2 · ownership.nature: These securities are held of record by U.S. Venture Partners XI, L.P. ("USVP XI"). Presidio Management Group XI, L.L.C. ("PMG XI"), the general partner of USVP XI, has sole voting and dispositive power with respect to the shares held by USVP XI. The Reporting Person is a managing member of PMG XI with additional rights with respect to the issuer's securities, and may be deemed to have sole voting and dispositive power with respect to such shares. Each of the foregoing persons disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 94,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000017 · edgar.xml · nonDerivative · entry 5 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,892 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5 · ownership.direct: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMG X Distribution. Shares are held directly by the Reporting Person. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 685,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000017 · edgar.xml · nonDerivative · entry 4 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by PMG X Disclosed balance after: 0 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F4 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by PMG X, without additional consideration to its members (the "PMG Distribution"). The Reporting Person, a director of the Issuer, is a managing member of PMG X with additional rights with respect to the shares, and may be deemed to have sole voting and dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities held by PMG X, except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 685,827 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000017 · edgar.xml · nonDerivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by PMG X Disclosed balance after: 685,827 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F3 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of the USVP X Funds, without additional consideration. The Reporting Person, a director of the Issuer, is a managing member of PMG X with additional rights with respect to the shares, and deemed to have sole voting and dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 83,814 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000017 · edgar.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 83,813 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), without additional consideration, to its partners. Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. The Reporting Person, a director of the Issuer, is a managing member of PMG X with additional rights with respect to such shares, and deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 2,619,872 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000017 · edgar.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 2,619,872 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · ownership.nature: Represents a pro-rata in-kind distribution of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund L.P. ("AFF X" and, together with USVP X, the "USVP X Funds"), without additional consideration, to its partners. Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the securities held by the USVP X Funds. The Reporting Person, a director of the Issuer, is a managing member of PMG X with additional rights with respect to such shares, and deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| March 03, 2021 Filed Mar 18, 2022 21:14 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | PurchaseCommon Stock | 350 | $52.07 | $18,224.50 |
DisclosureSEC source: 0001062993-22-008141 · form4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Spouse Disclosed balance after: 350 F1 · shares: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. F1 · balance_after: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. F1 · ownership.direct: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. F1 · ownership.nature: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 of Table I does not reflect previously reported transactions that occurred after 3/3/2021. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:46 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionSeries C Preferred Stock · Derivative | 54,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062391 · doc4.xml · derivative · entry 9 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By U.S.VenturePartners XII-A,L.P. Disclosed balance after: 0 Underlying: Common Stock · 14,677 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:46 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionSeries C Preferred Stock · Derivative | 1,073,793 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062391 · doc4.xml · derivative · entry 8 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By U.S VenturePartners XII,L.P. Disclosed balance after: 0 Underlying: Common Stock · 289,198 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:46 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionSeries B Preferred Stock · Derivative | 335,417 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062391 · doc4.xml · derivative · entry 7 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By U.S.VenturePartners XII-A,L.P. Disclosed balance after: 0 Underlying: Common Stock · 90,335 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:46 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionSeries B Preferred Stock · Derivative | 6,609,027 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062391 · doc4.xml · derivative · entry 6 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By U.S VenturePartners XII,L.P. Disclosed balance after: 0 Underlying: Common Stock · 1,779,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:46 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionCommon Stock | 14,677 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-062391 · doc4.xml · nonDerivative · entry 5 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By U.S.VenturePartners XII-A,L.P. Disclosed balance after: 105,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:46 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionCommon Stock | 90,335 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-062391 · doc4.xml · nonDerivative · entry 4 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By U.S.VenturePartners XII-A,L.P. Disclosed balance after: 90,335 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:46 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionCommon Stock | 289,198 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-062391 · doc4.xml · nonDerivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By U.S VenturePartners XII,L.P. Disclosed balance after: 2,069,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:46 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | ConversionCommon Stock | 1,779,969 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-062391 · doc4.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By U.S VenturePartners XII,L.P. Disclosed balance after: 1,779,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 3.713 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F3 · ownership.nature: Presidio Management Group XII, L.L.C. (PMG XII), the general partner of U.S. Venture Partners XII, L.P. and U.S. Venture Partners XII-A, L.P. (together, USVP XII), has sole voting and dispositive power with respect to the shares held by USVP XII. The reporting person is a managing member of PMG XII, and shares voting and dispositive power with respect to the shares held by USVP XII. The reporting person disclaims beneficial ownership of such holdings, except to the extent of his pecuniary interest in the shares. Read SEC document |
| December 08, 2020 Filed Dec 9, 2020 01:46 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | PurchaseCommon Stock | 95,238 | $21.00 | $1,999,998.00 |
DisclosureSEC source: 0001209191-20-062391 · doc4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,238 F1 · kind: The shares were purchased in the Issuer's initial public offering. Read SEC document |
| December 03, 2020 Filed Dec 8, 2020 00:58 UTC | ARS Pharmaceuticals, Inc. SBTX · Entity 883 | GrantStock Option (right to buy) · Derivative | 38,270 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001209191-20-062051 · doc4.xml · derivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,270 Underlying: Common Stock · 38,270 shares Expires 2030-12-02 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 36 months following December 3, 2020. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 81,996 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000022 · edgar.xml · nonDerivative · entry 5 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,996 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F5 · ownership.direct: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMGX Distribution. Shares are held directly by the Reporting Person. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 587,851 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000022 · edgar.xml · nonDerivative · entry 4 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by PMG X Disclosed balance after: 0 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F4 · ownership.nature: Represnts a pro-rata in-kind distribution of the Issuer's common stock held direction by PMG X, without additional consideration to its members (the "PMG Distribution"). The Reporting Person, a director of the Issuer, is a managing member of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities held by PMG X, except to the extent of any pecuniary interest therein. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 587,851 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000022 · edgar.xml · nonDerivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by PMG X Disclosed balance after: 587,851 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F3 · ownership.nature: Represnts a pro-rata in-kind distribution of the Issuer's common stock to PMG X from each of USVP X Funds, without additional consideration. The Reporting Person, a director of the Issuer, is a managing member of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by PMG X, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 71,840 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000022 · edgar.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by AFF X Disclosed balance after: 167,627 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · ownership.nature: Represnts a pro-rata in-kind distribuiont of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund L.P. ("AFF X") and, together with USVP X, the ("USVP X Funds"), without additional consideration, to its partners. Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the securities held by the USVPX Funds. The Reporting Person, a director of the Issuer, is a managing member of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 17, 2020 Filed Nov 20, 2020 02:01 UTC | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 2,245,605 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001527715-20-000022 · edgar.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by USVP X Disclosed balance after: 5,239,744 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · ownership.nature: Represnts a pro-rata in-kind distribuiont of the Issuer's common stock held directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund L.P. ("AFF X") and, together with USVP X, the ("USVP X Funds"), without additional consideration, to its partners. Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the securities held by the USVPX Funds. The Reporting Person, a director of the Issuer, is a managing member of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds, and disclaims beneficial ownership of such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| November 17, 2020 Filed Jan 21, 2021 22:59 UTC Amendment | Inari Medical, Inc. NARI · Entity 83035 | OtherCommon Stock | 81,996 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-21-000005 · edgar.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,791 F1 · kind: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F1 · price: Represents a pro-rata in-kind distribution of the Issuer's common stock, and not a purchase or sale, without additional consideration to their respective partners, members and assignees, as applicable. F2 · balance_after: The original Form 4 filed on November 19, 2020, is being amended by this Form 4 amendment solely to correct an adminstrative error, which incorrectly underreported the amount of shares owned by the Reporting Person listed in column 5 as 81,996 shares instead of 333,791.shares. F3 · ownership.direct: Represents a change in the form of ownership from indirect to direct by virtue of the receipt of shares in the PMGX Distribution. Shares are held directly by the Reporting Person. Read SEC document |
| June 22, 2020 Filed Mar 18, 2022 21:10 UTC | Inari Medical, Inc. NARI · Entity 83035 | PurchaseCommon Stock | 32 | $46.61 | $1,491.65 |
DisclosureSEC source: 0001562180-22-002817 · primarydocument.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Directly Owned by Spouse Disclosed balance after: 32 F1 · shares: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 reflects amounts held as of the date of this filing. F1 · ownership.direct: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 reflects amounts held as of the date of this filing. F1 · ownership.nature: Shares are being reported following the discovery that shares of the issuer were purchased in discretionary IRA accounts held by the spouse of the reporting person. The reporting person is not an owner of such IRA accounts. The total in Column 5 reflects amounts held as of the date of this filing. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionSeries C Preferred Stock · Derivative | 72,887 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032416 · doc4.xml · derivative · entry 10 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly Owned by AFF X Disclosed balance after: 0 Underlying: Common Stock · 72,887 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. 3. The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionSeries C Preferred Stock · Derivative | 2,278,331 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032416 · doc4.xml · derivative · entry 9 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly Owned by USVP X Disclosed balance after: 0 Underlying: Common Stock · 2,278,331 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. 3. The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionSeries B Preferred Stock · Derivative | 92,771 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032416 · doc4.xml · derivative · entry 8 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly Owned by AFF X Disclosed balance after: 0 Underlying: Common Stock · 92,771 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. 3. The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionSeries B Preferred Stock · Derivative | 2,899,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032416 · doc4.xml · derivative · entry 7 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly Owned by USVP X Disclosed balance after: 0 Underlying: Common Stock · 2,899,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. 3. The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionSeries A Preferred Stock · Derivative | 73,809 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032416 · doc4.xml · derivative · entry 6 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly Owned by AFF X Disclosed balance after: 0 Underlying: Common Stock · 73,809 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. 3. The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionSeries A Preferred Stock · Derivative | 2,307,142 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032416 · doc4.xml · derivative · entry 5 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly Owned by USVP X Disclosed balance after: 0 Underlying: Common Stock · 2,307,142 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.exercise_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F1 · derivative.expiration_date: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. 3. The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | GrantRestricted Stock Unit · Derivative | 8,947 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032416 · doc4.xml · derivative · entry 4 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,947 Underlying: Common Stock · 8,947 shares Expires not disclosed F3 · derivative.exercise_price: The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. F3 · price: The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. F3 · derivative.exercise_date: The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. F3 · derivative.expiration_date: The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionCommon Stock | 239,467 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032416 · doc4.xml · nonDerivative · entry 3 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly Owned by AFF X Disclosed balance after: 239,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. 3. The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | ConversionCommon Stock | 7,485,349 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-032416 · doc4.xml · nonDerivative · entry 2 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · Directly Owned by USVP X Disclosed balance after: 7,485,349 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Upon the closing of the Issuer's initial public offering, each share of preferred stock automatically converted into shares of the Issuer's common stock on a one-for-one basis. F2 · ownership.nature: The reported securities are owned directly by each of U.S. Venture Partners X, L.P. ("USVP X") and USVP X Affiliates Fund, L.P. ("AFF X") (together, the "USVP X Funds"). Presidio Management Group X, L.L.C. ("PMG X") is the general partner of each of the USVP X Funds and may be deemed to have sole voting and dispositive power over the reported securities held by the USVP X Funds. Jonathan D. Root, a director of the issuer, Irwin Federman, Steven Krausz, Richard Lewis, Paul Matteucci and Casey Tansey are the managing members of PMG X, who may be deemed to share voting and dispositive power over the reported securities held by the USVP X Funds. Such persons and entities disclaim beneficial ownership of the reported securities held by the USVP X Funds, except to the extent of any pecuniary interest therein. 3. The restricted stock unit vests in three equal annual installments beginning on May 27, 2020. Read SEC document |
| May 27, 2020 Filed May 27, 2020 22:38 UTC | Inari Medical, Inc. NARI · Entity 83035 | PurchaseCommon Stock | 251,795 | $19.00 | $4,784,105.00 |
DisclosureSEC source: 0001209191-20-032416 · doc4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,795 Read SEC document |
| April 23, 2019 Filed Apr 23, 2019 16:16 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | OtherCommon Stock | 121,020 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-010989 · doc4.xml · nonDerivative · entry 1 ROOT JONATHAN D · CIK 0001225480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On April 23, 2019, pursuant to the Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), dated as of December 5, 2018, by and among Mereo Biopharma Group PLC ("Mereo"), Mereo US Holdings Inc., Mereo Mergerco One Inc. ("Merger Sub") and the Issuer, Merger Sub merged with and into the Issuer, with the Issuer surviving as an indirect wholly-owned subsidiary of Mereo (the "Merger"). Pursuant to the Merger, the Issuer's stockholders received the right to receive (i) a certain number of American Depositary Shares, each representing five ordinary shares, 0.003 pounds par value per share, of Mereo and (ii) one contingent value right, which represents the contractual right to receive contingent payments if specified milestones are achieved within agreed time periods, subject to and in accordance with the CVR Agreement, dated April 23, 2019, by and among Computershare Inc. and Mereo (the "Merger Consideration") for each share of the Issuer's stock that they own. F2 · price: (Continued from footnote 1) Pursuant to the Merger, the Reporting Person disposed of all shares of Issuer common stock beneficially owned by it, and received the Merger Consideration for each share of Issuer common stock. Read SEC document |
| November 13, 2018 Filed Nov 13, 2018 22:18 UTC | INTERMOLECULAR INC IMI · Entity 154785 | SaleCommon Stock, $0.001 per share | 2,400 | $0.95 | $2,280.00 |
DisclosureSEC source: 0001548538-18-000004 · edgar.xml · nonDerivative · entry 6 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Steven Krausz Disclosed balance after: 97,593 F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document |
| November 12, 2018 Filed Nov 13, 2018 22:18 UTC | INTERMOLECULAR INC IMI · Entity 154785 | SaleCommon Stock, $0.001 per share | 2,100 | $0.96 | $2,006.76 |
DisclosureSEC source: 0001548538-18-000004 · edgar.xml · nonDerivative · entry 5 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner Tansey Casey M · CIK 0001474322 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Steven Krausz Disclosed balance after: 99,993 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $.95 to $.96, inclusive for sales made on November 12, 2018. The reporting persons undertake to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Irwin Federman, a director of the Issuer, and each of Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, Casey Tansey, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document |
| November 08, 2018 Filed Nov 14, 2018 01:13 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | OtherCommon Stock | 18,212 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 9 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Philip Young Disclosed balance after: 18,212 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document |
| November 08, 2018 Filed Nov 14, 2018 01:13 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | OtherCommon Stock | 18,982 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 8 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Jonathan Root Disclosed balance after: 18,982 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document |
| November 08, 2018 Filed Nov 14, 2018 01:13 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | OtherCommon Stock | 13,356 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 7 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by Paul Matteucci Disclosed balance after: 13,356 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document |
| November 08, 2018 Filed Nov 14, 2018 01:13 UTC | Inspire Medical Systems, Inc. INSP · Entity 1186 | OtherCommon Stock | 15,391 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001548538-18-000007 · edgar.xml · nonDerivative · entry 6 Presidio Management Group IX, L.L.C. · CIK 0001527715 · 10% owner U S Venture Partners IX L P · CIK 0001309185 · 10% owner FEDERMAN IRWIN · CIK 0001192391 · 10% owner KRAUSZ STEVEN M · CIK 0001190636 · 10% owner LIDDLE DAVID E · CIK 0001212726 · 10% owner Matteucci Paul A · CIK 0001370817 · 10% owner ROOT JONATHAN D · CIK 0001225480 · 10% owner YOUNG PHILIP M · CIK 0001048637 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · Directly owned by David Liddle Disclosed balance after: 15,391 F1 · kind: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F1 · price: Represents a pro-rata, in-kind distribution by U.S. Venture Partners IX, L.P. ("USVP IX"), without additional consideration, to its partners. F2 · ownership.direct: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. F2 · ownership.nature: This report is one of two reports each on a separate Form 4; however, these forms are related to the same transaction being filed by the reporting persons. The shares are held of record by USVP IX. Presidio Management Group IX, LLC ("PMG IX") is the general partner of USVP IX and may be deemed to have sole voting and dispositive power over the shares held by USVP IX. Casey Tansey, a director of the Issuer, and each of Irwin Federman, Steven M. Krausz, David E. Liddle, Paul A. Matteucci, Jonathan D. Root, and Philip M. Young, are managing members of PMG IX, and may be deemed to share voting and dispositive power over the shares held by USVP IX. Such persons and entities disclaim beneficial ownership of shares held by USVP IX, except to the extent of any proportionate pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.